# [[Oral_Diabetes_Drugs#Products:_Oral_Hypoglycemic_Agents|Oral hypoglecemic agents]] and their role in diabetes treatment. The focus was the recent meta analysis published in [http://content.nejm.org/cgi/content/full/356/24/2457?ijkey=9288cc5edfcb35c1e7f1bd5d974d1169d64cea0b NEJM], showing increase CV mortality with Rosiglitazone. The panel consensus was that while awaiting more safety data, for now those patients who are tolerating Rosiglitazone should continue taking them, whereas newly diagnosed patients should try alternative treatment. Also all PPAR agonists should be treated as distinct entities rather than having class effect.
# 12 different [[DiabetesOral_Diabetes_Drugs#Products:_Oral_Hypoglycemic_Agents DPP–IV inhibitors| diabetes products]] are in various stages of development, and there were about 55 abstracts talking about DPP–IV inhibitors. They are especially useful for:
#* The elderly
#* Those with renal insufficiency